Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1992 Aug;47(8):577–581. doi: 10.1136/thx.47.8.577

The management of tuberculous meningitis.

M Humphries
PMCID: PMC463911  PMID: 1412110

Full text

PDF
577

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ASHBY M., GRANT H. Tuberculous meningitis treated with cortisone. Lancet. 1955 Jan 8;268(6854):65–66. doi: 10.1016/s0140-6736(55)90003-9. [DOI] [PubMed] [Google Scholar]
  2. Acharya V. N., Kudva B. T., Retnam V. J., Mehta P. J. Adult tuberculous meningitis: comparative study of different chemotherapeutic regimens. J Assoc Physicians India. 1985 Sep;33(9):583–585. [PubMed] [Google Scholar]
  3. Allen M. B., Cooke N. J. Corticosteroids and tuberculosis. BMJ. 1991 Oct 12;303(6807):871–872. doi: 10.1136/bmj.303.6807.871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Arrington J. A. Meningeal tuberculoma. Semin Roentgenol. 1987 Jan;22(1):7–8. doi: 10.1016/0037-198x(87)90017-4. [DOI] [PubMed] [Google Scholar]
  5. BARCLAY W. R., EBERT R. H., LE ROY G. V., MANTHEI R. W., ROTH L. J. Distribution and excretion of radioactive isoniazid in tuberculous patients. J Am Med Assoc. 1953 Apr 18;151(16):1384–1388. [PubMed] [Google Scholar]
  6. BRODIE B. B., KURZ H., SCHANKER L. S. The importance of dissociaton constant and lipid-solubility in influencing the passage of drugs into the cerebrospinal fluid. J Pharmacol Exp Ther. 1960 Sep;130:20–25. [PubMed] [Google Scholar]
  7. Barling R. W., Selkon J. B. The penetration of antibiotics into cerebrospinal fluid and brain tissue. J Antimicrob Chemother. 1978 May;4(3):203–227. doi: 10.1093/jac/4.3.203. [DOI] [PubMed] [Google Scholar]
  8. Berenguer J., Moreno S., Laguna F., Vicente T., Adrados M., Ortega A., González-LaHoz J., Bouza E. Tuberculous meningitis in patients infected with the human immunodeficiency virus. N Engl J Med. 1992 Mar 5;326(10):668–672. doi: 10.1056/NEJM199203053261004. [DOI] [PubMed] [Google Scholar]
  9. Bhargava S., Gupta A. K., Tandon P. N. Tuberculous meningitis--a CT study. Br J Radiol. 1982 Mar;55(651):189–196. doi: 10.1259/0007-1285-55-651-189. [DOI] [PubMed] [Google Scholar]
  10. Bobrowitz I. D. Ethambutol in tuberculous meningitis. Chest. 1972 Jun;61(7):629–632. doi: 10.1378/chest.61.7.629. [DOI] [PubMed] [Google Scholar]
  11. Boman G., Ringberger V. A. Binding of rifampicin by human plasma proteins. Eur J Clin Pharmacol. 1974 Aug 23;7(5):369–373. doi: 10.1007/BF00558209. [DOI] [PubMed] [Google Scholar]
  12. Bullock M. R., Van Dellen J. R. The role of cerebrospinal fluid shunting in tuberculous meningitis. Surg Neurol. 1982 Oct;18(4):274–277. doi: 10.1016/0090-3019(82)90344-5. [DOI] [PubMed] [Google Scholar]
  13. Bullock M. R., Welchman J. M. Diagnostic and prognostic features of tuberculous meningitis on CT scanning. J Neurol Neurosurg Psychiatry. 1982 Dec;45(12):1098–1101. doi: 10.1136/jnnp.45.12.1098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Carlone N. A., Acocella G., Cuffini A. M., Forno-Pizzoglio M. Killing of macrophage-ingested mycobacteria by rifampicin, pyrazinamide, and pyrazinoic acid alone and in combination. Am Rev Respir Dis. 1985 Dec;132(6):1274–1277. doi: 10.1164/arrd.1985.132.6.1274. [DOI] [PubMed] [Google Scholar]
  15. Chambers S. T., Hendrickse W. A., Record C., Rudge P., Smith H. Paradoxical expansion of intracranial tuberculomas during chemotherapy. Lancet. 1984 Jul 28;2(8396):181–184. doi: 10.1016/s0140-6736(84)90478-1. [DOI] [PubMed] [Google Scholar]
  16. Chang C. M., Chan F. L., Yu Y. L., Huang C. Y., Woo E. Tuberculous meningitis associated with meningeal tuberculoma. J R Soc Med. 1986 Aug;79(8):486–487. doi: 10.1177/014107688607900820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Crosbie W. A. Fitness of North Sea divers. Lancet. 1984 Aug 25;2(8400):471–472. doi: 10.1016/s0140-6736(84)92951-9. [DOI] [PubMed] [Google Scholar]
  18. D'Oliveira J. J. Cerebrospinal fluid concentrations of rifampin in meningeal tuberculosis. Am Rev Respir Dis. 1972 Sep;106(3):432–437. doi: 10.1164/arrd.1972.106.3.432. [DOI] [PubMed] [Google Scholar]
  19. Donald P. R., Schoeman J. F., O'Kennedy A. Hepatic toxicity during chemotherapy for severe tuberculosis meningitis. Am J Dis Child. 1987 Jul;141(7):741–743. doi: 10.1001/archpedi.1987.04460070043019. [DOI] [PubMed] [Google Scholar]
  20. Donald P. R., Seifart H. I. Cerebrospinal fluid concentrations of ethionamide in children with tuberculous meningitis. J Pediatr. 1989 Sep;115(3):483–486. doi: 10.1016/s0022-3476(89)80862-5. [DOI] [PubMed] [Google Scholar]
  21. Donald P. R., Seifart H. Cerebrospinal fluid pyrazinamide concentrations in children with tuberculous meningitis. Pediatr Infect Dis J. 1988 Jul;7(7):469–471. doi: 10.1097/00006454-198807000-00003. [DOI] [PubMed] [Google Scholar]
  22. ELMENDORF D. F., Jr, CAWTHON W. U., MUSCHENHEIM C., McDERMOTT W. The absorption, distribution, excretion, and short-term toxicity of isonicotinic acid hydrazide (nydrazid) in man. Am Rev Tuberc. 1952 Apr;65(4):429–442. doi: 10.1164/art.1952.65.4.429. [DOI] [PubMed] [Google Scholar]
  23. Ellard G. A. Absorption, metabolism and excretion of pyrazinamide in man. Tubercle. 1969 Jun;50(2):144–158. doi: 10.1016/0041-3879(69)90020-8. [DOI] [PubMed] [Google Scholar]
  24. Ellard G. A., Ellard D. R., Allen B. W., Girling D. J., Nunn A. J., Teo S. K., Tan T. H., Ng H. K., Chan S. L. The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis. Am Rev Respir Dis. 1986 Jun;133(6):1076–1080. doi: 10.1164/arrd.1986.133.6.1076. [DOI] [PubMed] [Google Scholar]
  25. Ellard G. A., Humphries M. J., Gabriel M., Teoh R. Penetration of pyrazinamide into the cerebrospinal fluid in tuberculous meningitis. Br Med J (Clin Res Ed) 1987 Jan 31;294(6567):284–285. doi: 10.1136/bmj.294.6567.284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. FLETCHER A. P. C.S.F.--isoniazid levels in tuberculous meningitis. Lancet. 1953 Oct 3;265(6788):694–696. doi: 10.1016/s0140-6736(53)90420-6. [DOI] [PubMed] [Google Scholar]
  27. Forgan-Smith R., Ellard G. A., Newton D., Mitchison D. A. Pyrazinamide and other drugs in tuberculous meningitis. Lancet. 1973 Aug 18;2(7825):374–374. doi: 10.1016/s0140-6736(73)93211-x. [DOI] [PubMed] [Google Scholar]
  28. Fox W. Compliance of patients and physicians: experience and lessons from tuberculosis-I. Br Med J (Clin Res Ed) 1983 Jul 2;287(6384):33–35. doi: 10.1136/bmj.287.6384.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Fox W. The scope of the controlled clinical trial, illustrated by studies of pulmonary tuberculosis. Bull World Health Organ. 1971;45(5):559–572. [PMC free article] [PubMed] [Google Scholar]
  30. Girling D. J. The role of pyrazinamide in primary chemotherapy for pulmonary tuberculosis. Tubercle. 1984 Mar;65(1):1–4. doi: 10.1016/0041-3879(84)90024-2. [DOI] [PubMed] [Google Scholar]
  31. Gundert-Remy U., Klett M., Weber E. Concentration of ethambutol in cerebrospinal fluid in man as a function of the non-protein-bound drug fraction in serum. Eur J Clin Pharmacol. 1973 Aug;6(2):133–136. doi: 10.1007/BF00562440. [DOI] [PubMed] [Google Scholar]
  32. HUGHES I. E., SMITH H. Ethionamide: its passage into the cerebrospinal fluid in man. Lancet. 1962 Mar 24;1(7230):616–617. doi: 10.1016/s0140-6736(62)91602-1. [DOI] [PubMed] [Google Scholar]
  33. Harries A. D. Tuberculosis and human immunodeficiency virus infection in developing countries. Lancet. 1990 Feb 17;335(8686):387–390. doi: 10.1016/0140-6736(90)90216-r. [DOI] [PubMed] [Google Scholar]
  34. Hockaday J. M., Smith H. M. Corticosteroids as an adjuvant to the chemotherapy of tuberculous meningitis. Tubercle. 1966 Mar;47(1):75–91. doi: 10.1016/s0041-3879(66)80052-1. [DOI] [PubMed] [Google Scholar]
  35. Horne N. W. A critical evaluation of corticosteroids in tuberculosis. Bibl Tuberc. 1966;22:1–54. [PubMed] [Google Scholar]
  36. Horne N. W. Problems of tuberculosis in decline. Br Med J (Clin Res Ed) 1984 Apr 28;288(6426):1249–1251. doi: 10.1136/bmj.288.6426.1249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Humphries M. J., Teoh R., Lau J., Gabriel M. Factors of prognostic significance in Chinese children with tuberculous meningitis. Tubercle. 1990 Sep;71(3):161–168. doi: 10.1016/0041-3879(90)90069-k. [DOI] [PubMed] [Google Scholar]
  38. KINSELL L. W. The clinical application of pituitary adrenocorticotropic and adrenal steroid hormones. Ann Intern Med. 1951 Sep;35(3):615–651. doi: 10.7326/0003-4819-35-3-615. [DOI] [PubMed] [Google Scholar]
  39. Kaojarern S., Supmonchai K., Phuapradit P., Mokkhavesa C., Krittiyanunt S. Effect of steroids on cerebrospinal fluid penetration of antituberculous drugs in tuberculous meningitis. Clin Pharmacol Ther. 1991 Jan;49(1):6–12. doi: 10.1038/clpt.1991.2. [DOI] [PubMed] [Google Scholar]
  40. Kennedy D. H. Tuberculous meningitis. Lancet. 1981 Aug 1;2(8240):261–261. doi: 10.1016/s0140-6736(81)90512-2. [DOI] [PubMed] [Google Scholar]
  41. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle. 1991 Mar;72(1):1–6. doi: 10.1016/0041-3879(91)90017-m. [DOI] [PubMed] [Google Scholar]
  42. LORBER J. Treatment of tuberculous meningitis. Br Med J. 1960 Apr 30;1(5182):1309–1312. doi: 10.1136/bmj.1.5182.1309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Larbaoui D., Boulahbal F., Ait-Khaled A., Baghbagha D., Benseman H., Bensafar S. A. Etude des taux sériques et rachidiens de rifampicine (R. AMP). Arch Inst Pasteur Alger. 1972 1973;50-51:171–181. [PubMed] [Google Scholar]
  44. Lee C. S., Brater D. C., Gambertoglio J. G., Benet L. Z. Disposition kinetics of ethambutol in man. J Pharmacokinet Biopharm. 1980 Aug;8(4):335–346. doi: 10.1007/BF01059382. [DOI] [PubMed] [Google Scholar]
  45. Lee C. S., Gambertoglio J. G., Brater D. C., Benet L. Z. Kinetics of oral ethambutol in the normal subject. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 1):615–621. doi: 10.1002/cpt1977225part1615. [DOI] [PubMed] [Google Scholar]
  46. Lees A. J., MacLeod A. F., Marshall J. Cerebral tuberculomas developing during treatment of tuberculous meningitis. Lancet. 1980 Jun 7;1(8180):1208–1211. doi: 10.1016/s0140-6736(80)91676-1. [DOI] [PubMed] [Google Scholar]
  47. Loizou L. A., Anderson M. Intracranial tuberculomas: correlation of computerized tomography with clinico-pathological findings. Q J Med. 1982;51(201):104–114. [PubMed] [Google Scholar]
  48. Murray H. W., Brandstetter R. D., Lavyne M. H. Ventriculoatrial shunting for hydrocephalus complicating tuberculous meningitis. Am J Med. 1981 Apr;70(4):895–898. doi: 10.1016/0002-9343(81)90551-9. [DOI] [PubMed] [Google Scholar]
  49. Palur R., Rajshekhar V., Chandy M. J., Joseph T., Abraham J. Shunt surgery for hydrocephalus in tuberculous meningitis: a long-term follow-up study. J Neurosurg. 1991 Jan;74(1):64–69. doi: 10.3171/jns.1991.74.1.0064. [DOI] [PubMed] [Google Scholar]
  50. Paradoxical expansion of intracranial tuberculomas during chemotherapy. Lancet. 1984 Sep 29;2(8405):749–750. [PubMed] [Google Scholar]
  51. Parsons M. The treatment of tuberculous meningitis. Tubercle. 1989 Jun;70(2):79–82. doi: 10.1016/0041-3879(89)90031-7. [DOI] [PubMed] [Google Scholar]
  52. Peacock W. J., Deeny J. E. Improving the outcome of tuberculous meningitis in childhood. S Afr Med J. 1984 Oct 20;66(16):597–598. [PubMed] [Google Scholar]
  53. Phuapradit P., Supmonchai K., Kaojarern S., Mokkhavesa C. The blood/cerebrospinal fluid partitioning of pyrazinamide: a study during the course of treatment of tuberculous meningitis. J Neurol Neurosurg Psychiatry. 1990 Jan;53(1):81–82. doi: 10.1136/jnnp.53.1.81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Phuapradit P., Vejjajiva A. Treatment of tuberculous meningitis: role of short-course chemotherapy. Q J Med. 1987 Mar;62(239):249–258. [PubMed] [Google Scholar]
  55. Place V. A., Pyle M. M., De la Huerga J. Ethambutol in tuberculous meningitis. Am Rev Respir Dis. 1969 May;99(5):783–785. doi: 10.1164/arrd.1969.99.5.783. [DOI] [PubMed] [Google Scholar]
  56. Ramachandran P., Duraipandian M., Nagarajan M., Prabhakar R., Ramakrishnan C. V., Tripathy S. P. Three chemotherapy studies of tuberculous meningitis in children. Tubercle. 1986 Mar;67(1):17–29. doi: 10.1016/0041-3879(86)90028-0. [DOI] [PubMed] [Google Scholar]
  57. Ramachandran P., Duraipandian M., Reetha A. M., Mahalakshmi S. M., Prabhakar R. Long-term status of children treated for tuberculous meningitis in south India. Tubercle. 1989 Dec;70(4):235–239. doi: 10.1016/0041-3879(89)90017-2. [DOI] [PubMed] [Google Scholar]
  58. Roy T. K., Sircar P. K., Chandar V. Peritoneal ventriculo shunt in the management of tuberculous meningitis. Indian Pediatr. 1979 Nov;16(11):1023–1027. [PubMed] [Google Scholar]
  59. SMITH H. V. TUBERCULOUS MENINGITIS. Int J Neurol. 1964;4:134–157. [PubMed] [Google Scholar]
  60. Schanker L. S. Passage of drugs into and out of the central nervous system. Antimicrob Agents Chemother (Bethesda) 1965;5:1044–1050. [PubMed] [Google Scholar]
  61. Schoeman J. F., le Roux D., Bezuidenhout P. B., Donald P. R. Intracranial pressure monitoring in tuberculous meningitis: clinical and computerized tomographic correlation. Dev Med Child Neurol. 1985 Oct;27(5):644–654. doi: 10.1111/j.1469-8749.1985.tb14137.x. [DOI] [PubMed] [Google Scholar]
  62. Shepard W. E., Field M. L., James D. H., Jr, Tonkin I. L. Transient appearance of intracranial tuberculoma during treatment of tuberculous meningitis. Pediatr Infect Dis. 1986 Sep-Oct;5(5):599–601. doi: 10.1097/00006454-198609000-00028. [DOI] [PubMed] [Google Scholar]
  63. Sippel J. E., Mikhail I. A., Girgis N. I., Youssef H. H. Rifampin concentrations in cerebrospinal fluid of patients with tuberculous meningitis. Am Rev Respir Dis. 1974 May;109(5):579–580. doi: 10.1164/arrd.1974.109.5.579. [DOI] [PubMed] [Google Scholar]
  64. Stanley T. V., Balakrishnan V. Rifampicin in neonatal ventriculitis. Aust Paediatr J. 1982 Sep;18(3):200–201. doi: 10.1111/j.1440-1754.1982.tb02028.x. [DOI] [PubMed] [Google Scholar]
  65. Stottmeier K. D., Beam R. E., Kubica G. P. Determination of drug susceptibility of mycobacteria to pyrazinamide in 7H10 agar. Am Rev Respir Dis. 1967 Nov;96(5):1072–1075. doi: 10.1164/arrd.1967.96.5.1072. [DOI] [PubMed] [Google Scholar]
  66. Strang J. I., Kakaza H. H., Gibson D. G., Allen B. W., Mitchison D. A., Evans D. J., Girling D. J., Nunn A. J., Fox W. Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. Lancet. 1988 Oct 1;2(8614):759–764. doi: 10.1016/s0140-6736(88)92415-4. [DOI] [PubMed] [Google Scholar]
  67. Sunakorn P., Pongparit S., Wongrung S. Short course chemotherapy in tuberculous meningitis: a pilot trial. J Med Assoc Thai. 1980 Jun;63(6):340–345. [PubMed] [Google Scholar]
  68. Tandon P. N., Bhargava S. Effect of medical treatment on intracranial tuberculoma--a CT study. Tubercle. 1985 Jun;66(2):85–97. doi: 10.1016/0041-3879(85)90073-x. [DOI] [PubMed] [Google Scholar]
  69. Tang E. S., Chau A., Fong D., Humphries M. J. The treatment of multiple intracranial tuberculous abscesses: a case report. J Neurol. 1991 Jun;238(3):183–185. doi: 10.1007/BF00319688. [DOI] [PubMed] [Google Scholar]
  70. Teoh R., Humphries M. J., Hoare R. D., O'Mahony G. Clinical correlation of CT changes in 64 Chinese patients with tuberculous meningitis. J Neurol. 1989 Jan;236(1):48–51. doi: 10.1007/BF00314218. [DOI] [PubMed] [Google Scholar]
  71. Teoh R., Humphries M. J., O'Mahony G. Symptomatic intracranial tuberculoma developing during treatment of tuberculosis: a report of 10 patients and review of the literature. Q J Med. 1987 May;63(241):449–460. [PubMed] [Google Scholar]
  72. Teoh R., Poon W., Humphries M. J., O'Mahony G. Suprasellar tuberculoma developing during treatment of tuberculous meningitis requiring urgent surgical decompression. J Neurol. 1988 May;235(5):321–322. doi: 10.1007/BF00314183. [DOI] [PubMed] [Google Scholar]
  73. Watson J. M., Gill O. N. HIV infection and tuberculosis. BMJ. 1990 Jan 13;300(6717):63–65. doi: 10.1136/bmj.300.6717.63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Young R. C., Mitchell R. C., Brown T. H., Ganellin C. R., Griffiths R., Jones M., Rana K. K., Saunders D., Smith I. R., Sore N. E. Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. J Med Chem. 1988 Mar;31(3):656–671. doi: 10.1021/jm00398a028. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES